{"disease":{"id":"prevention-of-breast-carcinoma","name":"Prevention of Breast Carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"raloxifene","indication_name":"Prevention of Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evista","generic_name":"RALOXIFENE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"estrogen receptors","drug_class":"Estrogen Agonist/Antagonist","quality_score":75,"revenue":null,"mechanism":"Raloxifene binds to estrogen receptors, acting as an agonist in bone and an antagonist in uterine and breast tissues."},{"drug_id":"tamoxifen","indication_name":"Prevention of Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nolvadex","generic_name":"tamoxifen","company_name":"AstraZeneca (originally ICI)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6","drug_class":"SERM (Selective estrogen receptor modulator)","quality_score":55,"revenue":null,"mechanism":"Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density."},{"drug_id":"raloxifen","indication_name":"Prevention of Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"raloxifen","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, HLA class I histocompatibility antigen, A-3 alpha chain, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}